Kornimate/medical-research-clean huggingface dataset:
the effect of scapular stabilization exercises on the upper extremity in patients with chronic stroke

Conditions: Stroke

Summary: there is still no approved exact treatment for stroke, one of the leading causes of disability. neurorehabilitation is an important treatment option for stroke patients with anatomical and functional impairments in their interhemispheric connections. however, special techniques with high effectiveness are being investigated to increase the success of general rehabilitation. in this context, scapula-focused stabilization techniques have been used in stroke patients recently. in this randomized controlled study, investigators aimed to examine the effect of scapular stabilization exercises on upper extremity spasticity and motor function in addition to neurorehabilitation in patients with chronic stroke. 22 chronic stroke patients will be included in the study. the patients will be divided into two groups as scapular exercise group and control group using the simple randomization method. scapular stabilization exercises will be applied in combination with neurorehabilitation to the first group, while only neurorehabilitation will be applied to the control group. a 6-week (30 sessions) neurorehabilitation program will be applied to all groups, specially planned for the patient. spasticity of the patients participating in the study modified ashworth scale, upper extremity recovery levels brunnstrom recovery stage, upper extremity functions fugl meyer upper extremity scale and wolf motor function test, independence levels functional independence scale , activities of daily living will be evaluated with the modified barthel index and quality of life will be evaluated with the stroke specific quality of life scale. the first evaluation of the patients will be made before the treatment, and each patient will be evaluated after the 6-week exercise program. after all data are collected, in-group and intergroup comparisons will be made.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * 3 months past the stroke history * no previous history of stroke * mini mental test score ≥ 24 * upper extremity (elbow, wrist and finger) spasticity level to be 1-3 according to modified ashworth scale (mas) * upper extremity brunnstrom recovery stage 2-5 * no botulinum toxin injection for the affected upper extremity in the last 6 months * if he is using antispastic medication, his dose has not been changed in the last 1 month. * consent to participate in the study exclusion criteria: * having any neurological, psychiatric, orthopedic, unstable cardiovascular disease other than stroke * being pregnant * having upper extremity contractures

Keywords: stroke rehabilitation upper extremity stabilization scapula recovery of function spasticity
the phase iii clinical study of herombopag for the treatment of thrombocytopenia in chronic liver disease patients undergoing elective invasive surgery

Conditions: Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Summary: this study includes part a and part b. part a is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. part b is a multicenter, randomized, double-blind, placebo-controlled phase iii clinical study designed to evaluate the efficacy and safety of herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.


Eligibility criteria:
inclusion criteria: 1. males or females aged 18 years or older withc a child-pugh score of class a or class b; 2. platelet count less than 50×10\^9/l on baseline; 3. elective invasive procedures or surgeries that are planned. exclusion criteria: 1. any history of arterial or venous thrombosis, including partial or complete thrombosis; 2. evidence of thrombosis (partial or complete) in the main portal vein, portal vein branches, or any part of the splenic mesenteric system at screening; 3. portal vein blood flow velocity rate \<10 centimeters/second at screening; 4. there are other diseases that may cause thrombocytopenia.
first in human sad and mad study of inhaled td-0903, a potential treatment for ali associated with covid-19

Conditions: Acute Lung Injury (ALI) Associated With COVID-19; Inflammatory Lung Conditions Associated With COVID-19

Summary: this is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (part a and b) and multiple (part b) doses of inhaled td-0903.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) ≥ 18.0 and ≤ 32.0 kg/m2 at screening and weighs at least 50 kg. * medically healthy with no clinically significant medical history, physical examination, spirometry, vital signs or ecgs. * forced expiratory volume in 1 second (fev1) ≥80%. * no clinically significant abnormalities in the results of laboratory evaluations. * female subjects must be either of non-childbearing potential or if of childbearing potential, subject must not be pregnant or breastfeeding, and must agree to use a highly effective birth control method. * male subjects must agree to use condoms, in addition to the use of highly effective pregnancy prevention measures with female partners of childbearing potential. * understands the correct technique for the use the nebulizer device(s). * other inclusion criteria apply exclusion criteria: * history or presence of clinically significant medical or psychiatric condition. * abnormal ecg measurements at screening. * any signs of respiratory tract infection within 6 weeks of screening. * subject who has a current bacterial, parasitic, fungal, or viral infection; any infection requiring hospitalization or intravenous antibiotics within 6 months prior to screening. * positive test for sars-cov-2 * subject has any condition of the oro-laryngeal or respiratory tract. * uses or has used tobacco or nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, patches etc.) within 6 months prior to screening * additional exclusion criteria apply

Keywords: acute lung injury ali covid-19 coronavirus disease 2019 inflammatory lung conditions inflammatory lung disease
clinic or self-sampling for cervical cancer screening

Conditions: Cervical Cancer; HPV Infection

Summary: objective: the aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.

introduction: persistent infection with high-risk hpv strains is the main cause of cervical cancer. objective: the aim of this study was to determine the effect of clinic or self-sampling on cervical cancer screening participation, attitudes and anxiety in women. method: the study was conducted as a descriptive and randomized controlled study between october 2022 and december 2023 in ödemiş asm no. 2, ministry of health, republic of turkey. the first phase of the study was conducted with 309 women and the "introductory information form" and "attitude scale for early diagnosis of cervical cancer" were used to evaluate participation and attitudes towards cervical cancer screening. the second phase of the study was conducted as a randomized controlled trial with 110 women in the experimental (n=55) and control (n=55) groups. the women in the experimental group were trained before the procedure and were allowed to take samples from the vaginal area on their own. the women in the control group were sampled from the cervical region by the clinician. both groups were pretested before the procedure using the "descriptive information form" and the "state anxiety inventory" to measure anxiety. after the sampling procedure, the post-test was administered to the experimental and control groups using the "state anxiety inventory". results: according to the screening method preferences of the women, 34% (n=105) preferred a self-test, 18.4% (n=57) preferred a test performed by a clinician in a clinic, 3.9% (n=12) preferred no method, and 43.7% (n=135) preferred both methods. in the study, it was found that the self-test option increased participation in screening. the mean total score of the women was found to be 102.896±5.660. this result shows that women have high positive attitudes towards early diagnosis of cervical cancer. in the second stage of the study, it was observed that the descriptive characteristics of the experimental and control groups showed homogeneous distribution. while there was no significant difference between the experimental and control groups in terms of anxiety level in the pretest, it was found that the control group had a significantly higher anxiety level in the posttest. conclusion: in this study, it was observed that women had positive attitudes towards cervical cancer screening, self-sampling increased participation in screening and decreased anxiety levels.

Eligibility criteria:
inclusion criteria: must be able to perform self-test exclusion criteria: pregnancy, diagnosing the cervix

Keywords: cervical cancer hpv testing
therapeutic drug monitoring-based adalimumab de-escalation in non-infectious chronic uveitis

Conditions: Uveitis; Chronic Disease

Summary: uveitis and its complications are thought to account for 10 to 15% of preventable blindness in western countries. the diagnosis of chronic non-infectious uveitis (cnui) can be made after exclusion of pseudo uveitis or infectious uveitis, in the case of any persistent uveitis or uveitis with frequent relapses occurring less than 3 months after cessation of treatment. adalimumab (ada), an anti-tnfα monoclonal antibody, has marketing authorization and is widely used in the treatment of ucni as a relay to corticosteroids. the use of ada has been optimized, in particular through therapeutic drug monitoring (tdm), based on the determination of serum ada levels and anti-ada antibodies. recently, an article showed that a strategy of spacing ada administrations in ra patients with concentrations \>8 μg/ml was not inferior to standard.

there is currently no formal recommendation for spacing ada administration in patients with chronic noninfectious uveitis, but promising data from a recent retrospective study conducted by the croix-rousse team, led to the proposal of a decision support algorithm. following the example of what has been shown in rheumatoid arthritis, the investigators propose to compare a strategy of spacing ada administrations in patients with a satisfactory clinical response associated with high serum ada concentrations.

Eligibility criteria:
inclusion criteria: * informed and having signed the study consent form * age ≥ 18 years * nicu according to the standardization of uveitis nomenclature (sun) criteria * complete ophthalmological response for ≥ 48 weeks (96 weeks for uveitis related to behçet's disease), all treatments combined * on ada 40mg / 14 days for ≥ 24 weeks (i.e. achievement of the steady state for ada concentrations) * not having received systemic corticosteroid therapy for ≥ 12 weeks exclusion criteria: * inability or refusal to understand and/or sign the informed consent form to participate in the study. * inability and/or refusal to carry out the follow-up examinations required for the study. * modification of any background immunomodulatory treatment (e.g. methotrexate, hydroxychloroquine, mycophenolate, etc.) associated with ada, during the 12 weeks prior to inclusion. * uveitis suspected or proven to be of infectious origin * planned surgery (or other foreseeable medical event) requiring discontinuation of ada for the duration of the study.

Keywords: adalimumab uveitis therapeutic drug monitoring
safety and efficacy study of a caspase inhibitor in patients undergoing liver transplantation

Conditions: Liver Transplantation; Hepatitis; Cholestasis; Carcinoma, Hepatocellular

Summary: the purpose of the study is to test the safety and effectiveness of idn-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.

the occurrence of apoptosis in liver ischemia/reperfusion injury has been well characterized in animal models. in this context apoptosis has specifically been observed in sinusoidal endothelial cells and hepatocytes, and this has also been associated with an increase in activated caspase-3 in liver tissue extracts. the use of caspase inhibitors to prevent apoptosis during liver storage and transplantation may reduce ischemia/reperfusion injury and hence improve graft function after transplantation. suppression of apoptosis by caspase inhibitors may also allow for longer ischemic times allowing organs to be transported greater distances. in addition, suppression of apoptosis may lower the risk involved in using suboptimal donor organs.

Eligibility criteria:
inclusion criteria: * minimum adult age exclusion criteria: * fulminant hepatic failure (unos status i patients) * previous liver transplantation * patients undergoing split liver grafts * extrahepatic malignancy * if female, pregnant or lactating

Keywords: liver transplantation
the influence of obesity to esophageal reflux severity measured by ph-metri impedans on gastroesophageal reflux disease patients

Conditions: Disorder of Upper Esophageal Sphincter

Summary: to see a more convincing relationship between increased body mass index and the severity of esophageal reflux in gerd patients, gerd diagnosis should be performed with greater precision or precision. from the available data, it appears that no studies in indonesia have correlated the body mass index with the severity of esophageal reflux events measured by multical intraluminal intraluminal ph-metric in patients with gerd due to the invasive nature of the test. therefore, research needs to be done to assess the effect of increased body mass index on the severity of esophageal reflux as measured by multical intraluminal impedance ph-metric in gerd patients.

gastroesophageal reflux disease (gerd) prevalence is increasing worldwide. it is known that gerd correlates with obesity. in order to see further association between obesity and severity degree of esophageal reflux, gerd must be diagnosed with greater precision and accuracy. therefore, study to see the impact of obesity in esophageal reflux severity measured by multicanal intraluminal impedance ph-meter (mii-ph) in gerd patient is compulsory. the objective of this study is to explain the impact of obesity on severity of esophageal reflux in gerd patient measured by demeester score, hiatal hernia incidence, and the prolongation of acid exposure time in gerd patient. this cross-sectional study recruited patients from gastroenterology clinic, internal medicine department cipto mangunkusumo hospital during may-august 2017. patient with normal and obese body mass index (bmi) suspected having gerd were surveyed using gerdq to diagnose gerd in these patients. upper gastrointestinal endoscopy were performed to see hiatal hernia. all patients recruited underwent mii-ph examination to measure demeester score and acid exposure time. results were analyzed using bivariat analysis.

Eligibility criteria:
inclusion criteria: 1. gerd patients diagnosed by gerdq 2. adult patient age 18-60 years 3. patients with nutritional status based on normal bmi (18.5-24.9) and obesity (≥30) 4. willing to participate in research and sign informed consent exclusion criteria: 1. at the endoscopic examination found barrett's esophagus, peptic ulcer, severe gastritis, severe nsaid gastropathy, hemorrhage (melenae), gastric cancer, esophageal cancer 2. mii-ph check failed to install 3. patients are not cooperative 4. patients with acute psychiatric disorders 5. patients with severe heart trouble, persistent asthma patients, decompensated liver cirrhosis and chronic renal disease
a phase i study of ljm716 in japanese patients with advanced solid tumors

Conditions: Neoplasms

Summary: this study will evaluate safety and tolerability to estimate the mtdand/or recommended dose.

this is a phase i, open-label, dose-escalation study to establish the mtd and/or rde of ljm716 as single agent in japanese patients that have advanced solid tumors. the study consists of a dose escalation part and a dose expansion part.

Eligibility criteria:
inclusion criteria: 1. patients with the following indications: i) (dose escalation part only): her2 overexpressing locally advanced/ metastatic breast cancer or gastric cancer for which no effective treatment option exists: * for breast cancer: documented 3+ by immunohistochemistry, or amplification by in situ hybridization * for gastric cancer (including ge junction tumors): documented 3+ by immunohistochemistry, or 2+ by immunohistochemistry and amplification by in situ hybridization or, ii) (dose escalation part only): recurrent or metastatic scchn regardless of her2 status for which no effective treatment option exists or, iii) recurrent or metastatic escc regardless of her2 status for which no effective treatment option exists 2. ecog performance status of 0-2 3. must have recovered from the adverse effects of any prior surgery, radiotherapy or other antineoplastic therapy. alopecia and ctcae grade 1 peripheral neuropathy is acceptable. 4. willingness and ability to comply with all study procedures 5. written informed consent obtained prior to any screening procedures 6. during dose expansion part of the study, patients must have at least one measurable lesion as defined by recist v1.1 criteria

Keywords: cljm716, japanese patients, neoplasms
fitness and longevity in exercise

Conditions: HIV-1-infection; Aging

Summary: the study objective was to determine the safety and efficacy of aerobic exercise in older hiv-infected men in a randomized trial comparing different levels of exercise intensity.

the study was a randomized trial of moderate-intensity versus high-intensity aerobic exercise (aex) training in older hiv-infected adults. funding was provided by k23 ag024896 (pi, oursler) and the umb claude d. pepper older americans independence center p60 ag12583 (pi, goldberg). the central hypothesis was that high-intensity aex training is well-tolerated and significantly increases aerobic capacity in older hiv-infected adults. the study met its objectives: 1. scientific aims met: 1. high-intensity aex training significantly increases aerobic capacity 2. both moderate-intensity and high-intensity aex training improve ambulatory function and endurance. 3. activity of skeletal muscle oxidative enzymes is reduced, and associated with aerobic capacity. 2. feasibility objectives met: 1. aex training is safe and well-tolerated in older hiv-infected adults. 2. skeletal muscle punch biopsy is safe and well-tolerated in older hiv-infected adults. 3. preliminary data was collected on plasma biomarkers of inflammation.

Eligibility criteria:
inclusion criteria: * hiv+ * stable combination antiretroviral therapy (cart) exclusion criteria: * aids defining conditions in the prior six months * conditions that increase the risk of exercise training per the american college of sports medicine (acsm)

Keywords: exercise training intervention aerobic capacity
a multi-center real-world efficacy and safety of trastuzumab-deruxtecan in advanced gastric cancer

Conditions: Advanced Gastric Cancer

Summary: * institutions will be selected * this study aims to collect real-world data, targeting patients who started treatment with enhertu from september 2022, for clinical data collection * among patients treated with enhertu, those who have passed away or are no longer visiting due to hospice care will have their clinical data collected without consent until august 19, 2024 * for patients who are scheduled to receive enhertu treatment, are currently undergoing treatment, or have previously undergone treatment but experienced disease progression and are now receiving subsequent chemotherapy (i.e., patients with newly added data after registration) * efficacy evaluation

* institutions will be selected through the gastric cancer subcommittee of the korean cancer study group. * this study aims to collect real-world data, targeting patients who started treatment with trastuzumab-deruxtecan from september 2022, for clinical data collection. * among patients treated with trastuzumab-deruxtecan, those who have passed away or are no longer visiting due to hospice care will have their clinical data collected without consent until august 19, 2024. * for patients who are scheduled to receive enhertu treatment, are currently undergoing treatment, or have previously undergone treatment but experienced disease progression and are now receiving subsequent chemotherapy (i.e., patients with newly added data after registration), data will be collected with consent until march 31, 2027. * efficacy evaluation will include overall survival (os), progression-free survival (pfs), and tumor response rate (trr)

Eligibility criteria:
inclusion criteria: * patients aged 19 years or older. * patients with pathologically confirmed metastatic, recurrent, or unresectable gastric/gastroesophageal adenocarcinoma. * patients whose tumor tissue shows her2 immunohistochemistry (ihc) results of 3+ or 2+ with in-situ hybridization (ish) positivity. * patients who received trastuzumab deruxtecan as third-line or later treatment. exclusion criteria: * patients with her2-negative gastric cancer. * patients who did not provide consent to participate in the study. * patients who received trastuzumab deruxtecan as first-line or second-line treatment as part of a clinical trial.

Keywords: trastuzumab-deruxtecan
physical cold atmospheric plasma for the treatment of cervical intraepithelial neoplasia

Conditions: Cervical Intraepithelial Neoplasia

Summary: cervical intraepithelial neoplasia will be treated with physical low temperature plasma in the plasma cohort compared to watchful waiting in the control cohort. primary endpoint after 3-6 months: pathological remission. secondary endpoint: hpv remission.

the study was completed with less recruitment as it was planned due to overwhelming study success. the study was published in august 2023. a link has been added to the reference section.

Eligibility criteria:
inclusion criteria for cap: * histologically confirmed cin i / ii * reliable assessment of the radius of the portio and marginal borders of the lesions * written consent for treatment with low temperature plasma after reconnaissance inclusion criteria for control-group: * histologically confirmed cin i / ii * reliable assessment of the radius of the portio and marginal borders of the lesions * patients who want a waiting procedure and a control examination after 3-6 months exclusion criteria: * histologically confirmed cin iii * not fully visible transformation zone * an indication of invasive disease * expected lack of compliance of the patient or incapacity of the patient to understand the meaning and purpose of the clinical trial * severe cardio-vascular disease * lack of patient consent
the therapeutic effect of immunotherapy in patients with advanced lung squamous carcinoma

Conditions: Squamous Cell Lung Cancer

Summary: the aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-nsclc). the primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-nsclc patients. biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.

the medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.

Eligibility criteria:
inclusion criteria: * diagnosed with sq-nsclc; * receiving immunotherapy combined with or without chemotherapy as first-line treatment; * ≥ 18 years and ≤ 80 years old; * no previous treatment in the lungs or any other organ. exclusion criteria: * history of cancer treatment; * history of other malignant tumors; * irregular treatment or poor compliance; * incomplete clinical information or lost to follow-up.